Pharmafile Logo

Nerventra

- PMLiVE

Ocrevus surge keeps Roche smiling in Q3

MS drug is performing well, but immuno-oncology contender is in the doldrums

Celgene building

FDA turns down Celgene’s filing for multiple sclerosis drug

The application needs additional pharmacology information according to the US agency

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Teva launches personalised digital support for MS patients

Says its MS Care Programme is the first of its kind

- PMLiVE

Sanofi Genzyme brings The World Vs MS to Denmark

Firm's Communiqué Award winning campaign launches in another local market

- PMLiVE

Novartis trial marks ResearchKit first in MS

ElevateMS study will allow participants to contribute from smartphones

New analysis shows emergency hospital admissions for people with Multiple Sclerosis continue to rise

Updated data published by Wilmington Healthcare and the MS Trust highlights need for more preventative care for MS patients

Wilmington Healthcare

Case study: Multiple Sclerosis new medical device research

Our client wanted to find out how best to develop an implantable delivery device technology with add-on services in the Multiple Sclerosis market. We were tasked with finding out whether such a...

Research Partnership

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

Roche Basel Switzerland

Tecentriq growth offsets Avastin’s US decline at Roche

Shifts focus to newer therapies in anticipation of brewing biosimilar competition

- PMLiVE

Novartis talks the talk with new MS digital tools

Presents real world terms in online dictionary and Chrome Extension

- PMLiVE

Teva hit with largest-ever fine under US anti-corruption act

Company to pay $519m after promoting Copaxone in Russia, Ukraine and Mexico

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links